<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vtv Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/vtv-therapeutics-inc</link>
<description>Latest news and press releases for Vtv Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vtv-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d4d678dffbe2df12122b.webp</url>
<title>Vtv Therapeutics Inc</title>
<link>https://6ix.com/company/vtv-therapeutics-inc</link>
</image>
<item>
<title>vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development</description>
</item>
<item>
<title>vTv Therapeutics to Participate in the 38th Annual ROTH Conference</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-to-participate-in-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-to-participate-in-the-38th-annual-roth-conference</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development</description>
</item>
<item>
<title>vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update-14</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update-14</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the</description>
</item>
<item>
<title>vTv Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-upcoming-investor-130000968</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-upcoming-investor-130000968</guid>
<pubDate>Fri, 13 Feb 2026 13:00:00 GMT</pubDate>
<description>HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Thursday, February 26, 2026Time:</description>
</item>
<item>
<title>vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-amends-license-agreement-130000686</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-amends-license-agreement-130000686</guid>
<pubDate>Mon, 02 Feb 2026 13:00:00 GMT</pubDate>
<description>Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment immediately upon execution of the amended license agreement HIGH POINT, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive t</description>
</item>
<item>
<title>vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-m42-iros-announce-210500827</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-m42-iros-announce-210500827</guid>
<pubDate>Thu, 18 Dec 2025 21:05:00 GMT</pubDate>
<description>Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2DHIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions (IROS), a leading United Arab Emirates (UAE)-based contract research organization, has been submitted to the Department of Health (DOH) Abu Dhabi.</description>
</item>
<item>
<title>vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-reports-third-quarter-211500570</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-reports-third-quarter-211500570</guid>
<pubDate>Thu, 06 Nov 2025 21:15:00 GMT</pubDate>
<description>Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin,</description>
</item>
<item>
<title>vTv Therapeutics Announces New Appointments to its Scientific Advisory Board</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-appointments-scientific-120000021</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-appointments-scientific-120000021</guid>
<pubDate>Thu, 09 Oct 2025 12:00:00 GMT</pubDate>
<description>Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trialsHIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internatio</description>
</item>
<item>
<title>vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-innodia-symposium-120000708</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-innodia-symposium-120000708</guid>
<pubDate>Mon, 15 Sep 2025 12:00:00 GMT</pubDate>
<description>Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonistHIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the European Association for the Study of Diabetes (EASD) 61st Annual Meeting. INNODIA is an international non-for-profit organi</description>
</item>
<item>
<title>UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-upcoming-september-205700147</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-upcoming-september-205700147</guid>
<pubDate>Wed, 03 Sep 2025 20:57:00 GMT</pubDate>
<description>HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1</description>
</item>
<item>
<title>vTv Therapeutics to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-upcoming-september-120000162</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-upcoming-september-120000162</guid>
<pubDate>Wed, 03 Sep 2025 12:00:00 GMT</pubDate>
<description>HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1</description>
</item>
<item>
<title>vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-80-million-120000965</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-80-million-120000965</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes Topline data from CATT1 Phase 3 trial on track for second half 2026 HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adju</description>
</item>
<item>
<title>vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-reports-second-quarter-201500221</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-reports-second-quarter-201500221</guid>
<pubDate>Tue, 12 Aug 2025 20:15:00 GMT</pubDate>
<description>• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual property portfolio expanded • Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being invest</description>
</item>
<item>
<title>vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-uspto-allowance-120000042</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-uspto-allowance-120000042</guid>
<pubDate>Mon, 11 Aug 2025 12:00:00 GMT</pubDate>
<description>HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and</description>
</item>
<item>
<title>vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-first-study-120000264</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-first-study-120000264</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>Topline results from CATT1 Phase 3 trial expected in second half of 2026HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced the first study participant has been randomized in the Company’s CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment to insulin in adults with type 1 diabetes (T1D). Cadiseg</description>
</item>
<item>
<title>vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-h-c-120000563</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-participate-h-c-120000563</guid>
<pubDate>Wed, 11 Jun 2025 12:00:00 GMT</pubDate>
<description>HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright “HCW@H</description>
</item>
<item>
<title>vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-appoints-michael-tung-130000801</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-appoints-michael-tung-130000801</guid>
<pubDate>Mon, 19 May 2025 13:00:00 GMT</pubDate>
<description>HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time fo</description>
</item>
<item>
<title>vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-2025-first-200100635</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-2025-first-200100635</guid>
<pubDate>Thu, 15 May 2025 20:01:00 GMT</pubDate>
<description>Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results f</description>
</item>
<item>
<title>vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-reinitiation-screening-160000588</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-reinitiation-screening-160000588</guid>
<pubDate>Thu, 15 May 2025 16:00:00 GMT</pubDate>
<description>Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that screening has been reinitiated in the Company’s CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treat</description>
</item>
<item>
<title>vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-2024-fourth-213500433</link>
<guid isPermaLink="true">https://6ix.com/company/vtv-therapeutics-inc/news/vtv-therapeutics-announces-2024-fourth-213500433</guid>
<pubDate>Thu, 20 Mar 2025 21:35:00 GMT</pubDate>
<description>Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin be</description>
</item>
</channel>
</rss>